Marinus Pharmaceuticals (MRNS) Q3 2024 earnings summary

Executive summary

• ZTALMY (ganaxolone) net product revenue grew to $8.5M for Q3 2024 and $23.9M for the nine months, up from $5.4M and $13.0M in 2023, driven by increased patient uptake and over 200 patients on therapy.

• Full year 2024 ZTALMY revenue guidance narrowed to $33–$34M.

• The TrustTSC Phase 3 trial in Tuberous Sclerosis Complex and other Phase 3 trials failed to meet endpoints, leading to the suspension of further ganaxolone clinical development except for post-approval CDD commitments.

• Significant cost reductions, including a 45% workforce reduction in Q4 2024, were implemented to extend the cash runway, and a strategic alternatives review was initiated with Barclays as advisor.

• Cash and cash equivalents were $42.2M as of September 30, 2024, expected to fund operations into Q2 2025, but substantial doubt exists about going concern status.

Financial highlights

• Net loss was $24.2M for Q3 2024 and $98.7M for the nine months, compared to $33.0M and $99.6M in 2023.

• Total revenue was $8.5M for Q3 2024 and $24.3M for the nine months, up from $7.3M and $23.8M in 2023.

• Research and development expenses decreased to $16.3M for Q3 2024 and $61.3M for the nine months, from $23.7M and $73.0M in 2023.

• Selling, general and administrative expenses were $12.6M for Q3 2024 and $47.9M for the nine months, compared to $14.9M and $45.8M in 2023.

• Cash and cash equivalents at September 30, 2024: $42.2M (down from $150.3M at December 31, 2023).

Outlook and guidance

• 2024 ZTALMY net product revenue guidance narrowed to $33–$34M.

• Combined SG&A and R&D expenses projected at $135–$138M for 2024, including $20M in stock-based compensation.

• Cash runway expected into Q2 2025 following cost reduction measures, but additional funding or a strategic transaction is required for long-term viability.

• The company is exploring strategic alternatives, including a sale, partnership, or asset divestiture.